Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1394663rdf:typepubmed:Citationlld:pubmed
pubmed-article:1394663lifeskim:mentionsumls-concept:C0228174lld:lifeskim
pubmed-article:1394663lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:1394663lifeskim:mentionsumls-concept:C0033613lld:lifeskim
pubmed-article:1394663lifeskim:mentionsumls-concept:C0178796lld:lifeskim
pubmed-article:1394663lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:1394663lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:1394663lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:1394663lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:1394663pubmed:issue6lld:pubmed
pubmed-article:1394663pubmed:dateCreated1992-11-4lld:pubmed
pubmed-article:1394663pubmed:abstractTextNovel 4-arylpyrimidine derivatives were synthesized by the oxidation of 4-aryl-1,4-dihydropyrimidines, and their effects on anti-anoxic (AA) activity in mice and anti-lipid peroxidation (ALP) activity in rat brain mitochondria were investigated. Among these compounds, ethyl 6-methyl-2-phenyl-4-(4-pyridyl)-5-pyrimidinecarboxylate (4b) has AA activity (10 mg/kg, i.p.) and ethyl 6-methyl-4-(3-nitrophenyl)-2-phenyl-5-pyrimidinecarboxylate (4f) has ALP activity (73% inhibition at 10(-5) g/ml). The latter compound (100 mg/kg, i.p.) was also effective on arachidonate-induced cerebral edema in rats with comparable potency to that of vitamin E.lld:pubmed
pubmed-article:1394663pubmed:languageenglld:pubmed
pubmed-article:1394663pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1394663pubmed:citationSubsetIMlld:pubmed
pubmed-article:1394663pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1394663pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1394663pubmed:statusMEDLINElld:pubmed
pubmed-article:1394663pubmed:monthJunlld:pubmed
pubmed-article:1394663pubmed:issn0009-2363lld:pubmed
pubmed-article:1394663pubmed:authorpubmed-author:SugiyamaYYlld:pubmed
pubmed-article:1394663pubmed:authorpubmed-author:KunoAAlld:pubmed
pubmed-article:1394663pubmed:authorpubmed-author:KamitaniTTlld:pubmed
pubmed-article:1394663pubmed:authorpubmed-author:TakasugiHHlld:pubmed
pubmed-article:1394663pubmed:authorpubmed-author:KatsutaKKlld:pubmed
pubmed-article:1394663pubmed:issnTypePrintlld:pubmed
pubmed-article:1394663pubmed:volume40lld:pubmed
pubmed-article:1394663pubmed:ownerNLMlld:pubmed
pubmed-article:1394663pubmed:authorsCompleteYlld:pubmed
pubmed-article:1394663pubmed:pagination1452-61lld:pubmed
pubmed-article:1394663pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:1394663pubmed:meshHeadingpubmed-meshheading:1394663-...lld:pubmed
pubmed-article:1394663pubmed:meshHeadingpubmed-meshheading:1394663-...lld:pubmed
pubmed-article:1394663pubmed:meshHeadingpubmed-meshheading:1394663-...lld:pubmed
pubmed-article:1394663pubmed:meshHeadingpubmed-meshheading:1394663-...lld:pubmed
pubmed-article:1394663pubmed:meshHeadingpubmed-meshheading:1394663-...lld:pubmed
pubmed-article:1394663pubmed:meshHeadingpubmed-meshheading:1394663-...lld:pubmed
pubmed-article:1394663pubmed:meshHeadingpubmed-meshheading:1394663-...lld:pubmed
pubmed-article:1394663pubmed:meshHeadingpubmed-meshheading:1394663-...lld:pubmed
pubmed-article:1394663pubmed:meshHeadingpubmed-meshheading:1394663-...lld:pubmed
pubmed-article:1394663pubmed:meshHeadingpubmed-meshheading:1394663-...lld:pubmed
pubmed-article:1394663pubmed:year1992lld:pubmed
pubmed-article:1394663pubmed:articleTitleStudies on cerebral protective agents. I. Novel 4-arylpyrimidine derivatives with anti-anoxic and anti-lipid peroxidation activities.lld:pubmed
pubmed-article:1394663pubmed:affiliationNew Drug Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan.lld:pubmed
pubmed-article:1394663pubmed:publicationTypeJournal Articlelld:pubmed